You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 278 No. 17, November 5, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial

A. Anzueto, A. Jubran, J. A. Ohar, C. A. Piquette, S. I. Rennard, G. Colice, E. N. Pattishall, J. Barrett, M. Engle, K. A. Perret and B. K. Rubin
University of Texas Health Science Center at San Antonio, USA.

CONTEXT: Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. OBJECTIVE: To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. DESIGN: A prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). SETTING: Four US teaching hospitals. PARTICIPANTS: A total of 87 adult patients with the diagnosis of stable chronic bronchitis. MAIN OUTCOME MEASURES: Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). RESULTS: A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline. In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1 improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. CONCLUSION: Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Restoration of Mucociliary Transport in the Fluid-DepletedTrachea by Surface-Active Instillates
Ballard et al.
Am. J. Respir. Cell Mol. Bio. 2006;34:500-504.
ABSTRACT | FULL TEXT  

Impaired recycling of surfactant-like liposomes in type II pneumocytes from injured lungs
Muller et al.
Thorax 2003;58:127-134.
ABSTRACT | FULL TEXT  

Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD
Johnson and Rennard
Chest 2001;120:258-270.
ABSTRACT | FULL TEXT  

Function and Composition of Pulmonary Surfactant and Surfactant-Derived Fatty Acid Profiles Are Altered in Young Adults With Cystic Fibrosis
Meyer et al.
Chest 2000;118:164-174.
ABSTRACT | FULL TEXT  

Exogenous Surfactant Therapy and Mucus Rheology in Chronic Obstructive Airway Diseases
Banerjee and Puniyani
J Biomater Appl 2000;14:243-272.
ABSTRACT  

An In Vitro Comparison of the Mucoactive Properties of Guaifenesin, Iodinated Glycerol, Surfactant, and Albuterol
Rubin
Chest 1999;116:195-200.
ABSTRACT | FULL TEXT  

Emerging Therapies for Cystic Fibrosis Lung Disease
Rubin
Chest 1999;115:1120-1126.
FULL TEXT  

'Clear-ability' and Clarity in Medical Writing
Kissoon and Rubin
JAMA 1998;279:582-583.
FULL TEXT  

AEROSOLIZED SURFACTANT IMPROVES PULMONARY FUNCTION IN BRONCHITIS
JWatch General 1997;1997:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.